PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRovalpituzumab tesirine
Rovalpituzumab tesirine
Rovalpituzumab tesirine is an antibody drug conjugate pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against delta-like protein 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Small cell lung carcinomaD055752——633—111
Lung neoplasmsD008175HP_0100526C34.90533——9
ArthritisD001168HP_0001369M05-M142—1——3
Disease progressionD018450————1——1
Crohn diseaseD003424EFO_0000384K50——1——1
Inflammatory bowel diseasesD015212EFO_0003767———1——1
ColitisD003092EFO_0003872K52.9——1——1
Breast neoplasmsD001943EFO_0003869C50——1——1
Neoplasm metastasisD009362EFO_0009708———1——1
Psoriatic arthritisD015535EFO_0003778L40.5——1——1
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8022———3
Neuroendocrine carcinomaD018278——21———2
PainD010146EFO_0003843R52—2———2
Prostatic neoplasmsD011471—C6111———1
CarcinomaD002277—C80.011———1
Pancreatic neoplasmsD010190EFO_0003860C2511———1
GlioblastomaD005909EFO_0000515—11———1
MelanomaD008545——11———1
Papillary thyroid cancerD000077273——11———1
ThalassemiaD013789EFO_1001996D56—1———1
Show 8 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.92————2
Healthy volunteers/patients———2————2
Type 2 diabetes mellitusD003924EFO_0001360E111————1
Systemic sclerodermaD012595EFO_0000717M34.01————1
Lung diseasesD008171HP_0002088J98.41————1
Interstitial lung diseasesD017563HP_0006530J84.891————1
Diffuse sclerodermaD045743EFO_0000404—1————1
SclerosisD012598——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRovalpituzumab tesirine
INNrovalpituzumab tesirine
Description
Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL3990011
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDP256HB60FF (ChemIDplus, GSRS)
Target
Agency Approved
DLL3
DLL3
Organism
Homo sapiens
Gene name
DLL3
Gene synonyms
NCBI Gene ID
Protein name
delta-like protein 3
Protein synonyms
delta-like 3, Delta3, Drosophila Delta homolog 3
Uniprot ID
Mouse ortholog
Dll3 (13389)
delta-like protein 3 (Q9QWZ7)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 646 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
31 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use